Fig. 1From: Observational cohort study of rilpivirine (RPV) utilization in EuropeOverview of EuroSIDA participants included in the analysis. VF: first two consecutive VL > 50 copies/mL after >6 months from initiation of RPV/RFV-based regimens. *≥2 Viral load measures after baselineBack to article page